聚(ADP-核糖)聚合酶抑制剂耐药机制的研究进展
Research progress of resistance mechanism on PARPi
作者：李克敏;尹如铁;
Author：
收稿日期： 年卷（期）页码：2019,34(02):-183-186
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：聚(ADP-核糖)聚合酶抑制剂;耐药性;同源重组;卵巢癌;DNA修复缺陷;机制;研究进展
Key words：
基金项目：
中文摘要
聚(ADP-核糖)聚合酶抑制剂(PARPi)的发现及临床应用是卵巢恶性肿瘤治疗的重大突破。不仅给同源重组DNA修复缺陷的卵巢癌患者带来福音,而且无同源重组DNA修复缺陷的患者也能从中获益。然而,随着PARPi的临床应用增加,对其产生耐药的风险也明显增加。现系统概述了PARPi耐药的产生机制及其临床应对的可能策略。
参考文献
[1]Cancer Genome Atlas Research Network.Integrated genomic analyses of ovarian carcinoma[J].Nature,2011,474(7353):609-615.
[2]Farmer H,Mc Cabe N,Lord CJ,et al.Targeting the DNArepairdefect in BRCA mutant cells as a therapeutic strategy[J].Nature,2005,434(7035):917-921.
[3]Mc Cabe N,Lord CJ,Tutt AN,et al.BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly(ADP-Ribose)polymerase:An issue of potency[J].Cancer Biol Ther,2005,4(9):934-936.
[4]Rafnar T,Gudbjartsson DF,Sulem P,et al.Mutations in BRIP1 confer high risk of ovarian cancer[J].Nat Genet,2011,43(11):1104-1107.
[5]Walsh T,Casadei S,Lee MK,et al.Mutationsin 12 genes for inherited ovarian,fallopian tube,and peritoneal carcinoma identifiedby massively parallel sequencing[J].Proc Natl Acad Sci USA,2011,108(44):18032-18037.
[6]Shen Y,Rehman FL,Feng Y,et al.BMN673,anovel and highly potent PARP1/2 inhibitor for the treatment of human can cers with DNA repairde ficiency[J].Clin Cancer Res,2013,19(18):5003-5015.
[7]Murai J,Huang SY,Renaud A,et al.Stereospecific PARPtrapping by BMN673 and comparison with olaparib and rucaparib[J].Mol Cancer Ther,2014,13(2):433-43.
[8]Smith MA,Hampton OA,Reynolds CP,et al.Initialtesting(stage 1)of the PARP inhibitor BMN 673 by the pediatric preclinical testing program:PALB2 mutation predicts exceptional in vivo response to BMN673[J].Pediatr Blood Cancer,2015,62(1):91-98.
[9]Wang C,Jette N,Moussienko D,et al.ATM-deficient colorectal cancer cells are sensitive to the PARP inhibitor Olaparib[J].Transl Oncol,2017,10(2):190-196.
[10]Barber LJ,Sandhu S,Chen L,et al.Second arymutations in BRCA2 associated with clinical resistance to a PARP inhibitor[J].J Pathol,2013,229(3):422-429.
[11]Norquist B,Wurz KA,Pennil CC,et al.Secondary somaticmutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas[J].J Clin Oncol,2011,29(22):3008-3015.
[12]Bunting SF,Callén E,Wong N,et al.53BP1 inhibit shomologous recombination in Brca1-deficient cells by blocking resection of DNA Breaks[J].Cell,2010,141(2):243-254.
[13]Makvandi M,Xu K,Lieberman BP,et al.Aradiotracer strategy to quantify PARP-1 expression in vivo provides a biomarker that can enable patient selection for PARP inhibitor therapy[J].Cancer Res,2016,76(15):4516-4524.
[14]Sugimura K,Takebayashi S,Taguchi H,et al.PARP-1ensures regulation of replication fork progression by homologous recombination on damaged DNA[J].J Cell Biol,2008,183(7):1203-1212.
[15]Panzarino NJ,John S,Day A,etal.Replicationfork stability confers chemoresistance in BRCA-deficient cells[J].Nature,2016,535(7612):382-387.
[16]Ira G,Pellicioli A,Balijja A,et al.DNA endresection,homologous recombination and DNA damage checkpoint activation require CDK1[J].Nature,2004,431(7011):1011-1017.
[17]Blazek D,Kohoutek J,Bartholomeeusen K,et al.The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes[J].Genes Dev,2011,25(20):2158-2172.
[18]Bajrami I,Frankum JR,Konde A,et al.Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity[J].Cancer Res,2014,74(1):287-297.
[19]Johnson SF,Cruz C,Greifenberg AK,et al.CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-typeand mutated models of triple-negative breast cancer[J].Cell Rep,2016,17(9):2367-2381.
[20]Alagpulinsa DA,Ayyadevara S,Yaccoby S,et al.Shmookler Reis,Cyclin-dependent kinase inhibitor,dinaciclib,impairs homologous recombinationand sensitizes multiple myeloma cells to PARP inhibition[J].Mol Cancer Ther,2016,15(2)241-250.
[21]Garcia TB,Snedeker JC,Baturin D,et al.A small molecule inhibitor of WEE1,AZD1775,synergizes with olaparib by impairing homologous recombination and enhancing DNAdamage and apoptosis in acute leukemia[J].Mol Cancer Ther,2017,16(10):2058-2068.
[22]Karnak D,Engelke CG,Parsels LA,et al.Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer[J].Clin Cancer Res,2014,20(19):5085-5096.
[23]Do K,Wilsker D,Ji J,et al.Phase I study of singleagent AZD1775(MK-1775),a Wee1 kinase inhibitor,in patients with refractory solid tumors[J].J Clin Oncol,2015,33(30):3409-3415.
[24]Cruz C,Castroviejo-Bermejo M,Gutiérrez-Enríquez S,et al.RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer[J].Ann Oncol,2018,29(5):1203-1210.
[25]Teng PN,Bateman NW,Darcy KM,et al.Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian,endometrial,and cervical cancer cells[J].Gynecol Oncol,2015,136(3):554-561.
[26]Rottenberg S,Jaspers JE,Kersbergen A,et al.High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs[J].Proc Natl Acad Sci USA,2008,105(44):17079-17084.
[27]Du Y,Yamaguchi H,Wei Y,et al.Blocking c-metmediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors[J].Nat Med,2016,22(2):194-201.
[28]Tapodi A,Debreceni B,Hanto K,et al.Pivotalrole of Akt activation in mitochondrial protection and cell survival by poly(ADPribose)polymerase-1 inhibition in oxidative stress[J].J Biol Chem,2005,280(42):35767-35775.
[29]Veres B,Radnai B,Gallyas FJr,et al.Regulation of kinasecascades and transcription factors by a poly(ADP-ribose)polymerase-1 inhibitor,4-hydroxyquinazoline,in lipopolysaccharide-induced inflammation in mice[J].J Pharmacol Exp Ther,2004,310(1):247-255.
[30]Choi YE,Meghani K,Brault ME,et al.Platinum and PARPinhibitor resistance due to overexpression of microRNA-622in BRCA1-mutant ovarian cancer[J].Cell Rep,2016,14(3):429-439.
【关闭】
